Biomatrix
This article was originally published in The Gray Sheet
Executive Summary
FDA accepts for filing firm's premarket approval application for Synvisc, an injectable elastoviscous fluid for treatment of arthritic knees. Biomatrix submitted its PMA for the osteoarthritis treatment in May